中国临床肿瘤学年度研究进展2015 6. Winer E, Gralow J, Diller L, et al. Clinical Cancer Advances 2008 Major Research Advances in Cancer Treatment, Prevention, and Screening6A Report From the American Society of Clinical Oncology. J Clin Once 2009,27:812-826 7. Krismg, Benowitz Sl, Adams S, et al. Clinical Cancer Advances 2010: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol, 2010, 28: 5327-5347 8. Vogelzang NJ, Benowitz Sl, Adams S, et al. Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Onco, 2012. 30: 88-109 9. Roth BJ, Krilov L, Adams S, et al. Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol, 2013, 31: 131-161 10. Patel JD, Krilov L, Adams S, et al. Clinical Cancer Advances 2013: Annual Report on Progress Against Cance From the American Society of Clinical Oncology. J Clin Oncol, 2014, 32: 129-160 11. Masters GA, Krilov L, Bailey HH, et al. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol, 2015, 33: 786-809. 12. Dizon DS, Krilov L, Cohen E, et al. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol, 2016, 34: 987-1011 13. Yang JC, Wu YL. Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma(LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised 1s phase 3 trials. Lancet Oncol, 2015, 16: 141-151 4. Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and .UX- Lung 6. Lancet Oncol, 2015, 16: 830-838 15. Zhou C. Wu Yl. Chen g,et al. beyond: a Randomized double- Blind placebo-Controlled, multicenter Phase II Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol, 2015.33: 2197-2204 16. Zhou Q, Cheng Y, Yang J, et al. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR(CTONGO806 ) a multicenter randomized trial Ann oncol,2014,25:2385-2391 7. Deng y Chi P Lan P et al. A multi-center randomized controlled trial of mFOLFoX6 with or without radiation in neoadjuvant treatment of local advanced rectal cancer( FOWARC study): Preliminary results. J Clin Oncol 2015, 33 (suppl; abstr 3500). 18. LiJ, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer(CONCUR): a randomised, double-blind, placebo- controlled, phase 3 trial. Lancet Oncol, 2015, 16: 619-629 19. Xu R-H, Shen L, Wang K,et al. A randomized, double-blind, parallel-group, placebo-controlled, multicenter phase I clinical study of famitinib in the treatment of advanced metastatic colorectal cancer. J Clin Oncol 2015, 33: (suppl 3; abstr 513). 20. Xu J, Xia J, Gu Y, et al. Effect of preoperative hepatic and regional arterial chemotherapy on metachronous liver metastasis after curative colorectal cancer resection: A prospective, multicenter, randomized controlled trial. J Clin Oncol, 2015, 33: (suppl 3; abstr 511). 21. Li J, Qin S, Xu J,et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm. phase I trial. J Clin Oncol, 2013, 31: 3219-3225 22. Wang J, Xu R, Li J, et al. Randomized multicenter phase II study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally 1010 中国临床肿瘤学年度研究进展 2015 6. Winer E，Gralow J，Diller L，et al. Clinical Cancer Advances 2008：Major Research Advances in Cancer Treatment，Prevention，and ScreeningóA Report From the American Society of Clinical Oncology. J Clin Oncol， 2009，27：812-826. 7. Krismg，Benowitz SI，Adams S，et al. Clinical Cancer Advances 2010：Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol，2010，28：5327-5347. 8. Vogelzang NJ，Benowitz SI，Adams S，et al. Clinical Cancer Advances 2011：Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Onco，2012，30：88-109. 9. Roth BJ，Krilov L，Adams S，et al. Clinical Cancer Advances 2012：Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol，2013，31：131-161. 10. Patel JD，Krilov L，Adams S，et al. Clinical Cancer Advances 2013：Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol，2014，32：129-160. 11. Masters GA，Krilov L，Bailey HH，et al. Clinical cancer advances 2015：Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol，2015，33：786-809. 12. Dizon DS，Krilov L，Cohen E，et al. Clinical Cancer Advances 2016：Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol，2016，34：987-1011. 13. Yang JC，Wu YL，Schuler M，et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma （LUX-Lung 3 and LUX-Lung 6）：analysis of overall survival data from two randomised， phase 3 trials. Lancet Oncol，2015，16：141-151. 14. Yang JC，Sequist LV，Geater SL，et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations：a combined post-hoc analysis of LUX-Lung 2，LUX-Lung 3，and LUX-Lung 6. Lancet Oncol，2015，16：830-838. 15. Zhou C，Wu YL，Chen G，et al. BEYOND：A Randomized，Double-Blind，Placebo-Controlled，Multicenter， Phase Ⅲ Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol，2015，33：2197-2204. 16. Zhou Q，Cheng Y，Yang JJ，et al. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR （CTONG0806）：a multicenter randomized trial. Ann Oncol，2014，25：2385-2391. 17. Deng Y，Chi P，Lan P，et al. A multi-center randomized controlled trial of mFOLFOX6 with or without radiation in neoadjuvant treatment of local advanced rectal cancer （FOWARC study）：Preliminary results. J Clin Oncol， 2015，33：（suppl；abstr 3500）. 18. Li J，Qin S，Xu R，et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer （CONCUR）：a randomised，double-blind，placebo￾controlled，phase 3 trial. Lancet Oncol，2015，16：619-629. 19. Xu R-H，Shen L，Wang K，et al. A randomized，double-blind，parallel-group，placebo-controlled，multicenter， phase Ⅱ clinical study of famitinib in the treatment of advanced metastatic colorectal cancer. J Clin Oncol， 2015，33：（suppl 3；abstr 513）. 20. Xu J，Xia J，Gu Y，et al. Effect of preoperative hepatic and regional arterial chemotherapy on metachronous liver metastasis after curative colorectal cancer resection：A prospective，multicenter，randomized controlled trial. J Clin Oncol，2015，33：（suppl 3；abstr 511）. 21. Li J，Qin S，Xu J，et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer：results from a randomized，placebo-controlled，parallel-arm，phase Ⅱ trial. J Clin Oncol，2013，31：3219-3225. 22. Wang J，Xu R，Li J，et al. Randomized multicenter phase Ⅲ study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally